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Background
Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the ef-
fective chemotherapeutic regimens for patients with advanced stage marginal zone lym-
phoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL 
are not well understood.
Methods
Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL 
treated with R-CVP as a first-line therapy from 15 institutions were retrospectively 
analyzed. Patients’ clinical and laboratory data at diagnosis were collected by review of 
medical records.
Results
A total of 80 patients were analyzed. Bone marrow involvement was observed in 30% 
cases. Twelve patients (15%) had nodal MZL, and 41.3% patients exhibited multiple mu-
cosa-associated lymphoma tissue sites. Overall response rate was 91.3%, including 
73.8% achieving complete response. Advanced MZL patients treated with R-CVP showed 
a 3-year progression-free survival (PFS) rate of 69.6%. Prognostic markers significantly 
affecting PFS in univariate analysis were platelet to lymphocyte ratio (PLR, ＜95 vs. ≥95, 
P=0.014), serum albumin (≤3.9 vs. ＞3.9 g/dL, P=0.008), and the International 
Prognostic Index (IPI) score (1 vs. 2‒4, P=0.032). In multivariate analysis, only PLR (＜95 
vs. ≥95, HR 0.367, 95% CI, 0.139‒0.971, P=0.043) was an independent risk factor for 
PFS.
Conclusion
PLR ≥95 at diagnosis is an independent prognostic marker for PFS in advanced stage 
MZL patients treated with R-CVP. This marker may aid clinicians in predicting the response 
to R-CVP chemotherapy in stage III and IV MZL patients.
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INTRODUCTION
Marginal zone lymphoma (MZL) is a distinct subgroup 
of non-Hodgkin's lymphoma (NHL) that typically follows 
an indolent clinical course and has a long survival period 
[1]. In Korea, MZL accounts for 20.4% of all NHL, and 
is the second most frequent histological subtype after diffuse 
large B-cell lymphoma (DLBCL) [2].
For MZL with localized stage, regardless of subtype, it 
is well known that local modalities (such as radiotherapy 
or surgery) can be used to achieve good disease control. 
However, local therapy is inadequate in disseminated disease, 
which comprises at least a quarter of cases, leading to inves-
tigations for effective chemotherapy regimens [3].
After the introduction of rituximab, a chimeric monoclonal 
antibody directed against the B-cell-specific antigen CD20, 
into regimens targeted against MZL, rituximab in combina-
tion with other chemotherapeutic agents has shown promis-
ing results compared to conventional chemotherapy alone 
[4, 5]. Among the studied regimens, chemotherapy comprised 
of rituximab plus cyclophosphamide, vincristine, and pre-
dnisone (R-CVP) has demonstrated comparable overall re-
sponse rates (ORR), complete remission (CR) rates, and sur-
vival compared to other regimens containing rituximab [6].
The International Prognostic Index (IPI), although origi-
nally intended for use in patients with aggressive lymphoma 
[7], has been extensively applied, even in indolent 
lymphomas. However, it appears to have limited discriminat-
ing power, as the majority of patients are allocated to the 
favorable risk group [8]. Other prognostic indexes, such as 
the Follicular Lymphoma International Prognostic Index 
(FLIPI); Glasgow Prognostic Score (GPS), an inflammation- 
based prognostic score; or Marginal Zone Lymphoma 
Prognostic Index (MZLPI), have been proposed by different 
international groups that have mainly focused on in-
dolent-nature lymphomas [9-11].
Still, the prognostic factors that affect the outcome of 
MZL patients are not well understood. And after the in-
troduction of rituximab, the relevance of previously recog-
nized prognostic factors in other hematologic cancers has 
undergone reassessment [12]. Studies in various cancers have 
demonstrated that an elevation of neutrophils, platelets, 
monocytes, neutrophil to lymphocyte ratio (NLR), or platelet 
to lymphocyte ratio (PLR), or the decrease of serum albumin 
(SA) was associated with some unfavorable clinico-patho-
logic features [13-15]. The relationship of poor prognosis 
and the elevation of white blood cells, platelets, or associated 
ratios may be explained through an inflammatory process 
elicited by cancer cells [10, 16, 17]. Studies on platelets 
have shown that they might play an essential role in tumor 
spreading and growth [18]. Protective effects of lymphocytes 
as part of the immune surveillance system have also been 
investigated [19].
In this study, we aim to demonstrate whether the pretreat-
ment levels of various inflammatory markers and/or conven-
tional prognostic markers, can be prognostic indicators in 
patients treated with R-CVP for MZL.
MATERIALS AND METHODS
After obtaining approval from the Institutional Review 
Board (IRB) of Dong-A University Hospital, patients with 
the diagnosis of advanced stage MZL from 15 different in-
stitutions in Korea between August 2006 and June 2013 
were retrospectively evaluated. The IRB granted a waiver 
of informed consent based on the design of the study 
(retrospective data analysis study only, with no interactions 
with subjects/patients). Inclusion criteria comprised biop-
sy-confirmed diagnosis of MZL with advanced stage (Ann 
Arbor stage III/IV) and treatment with at least one cycle 
of R-CVP therapy with curative intent. Patients were ex-
cluded if they had prior chemotherapy other than R-CVP, 
were on rituximab maintenance therapy after R-CVP, or 
if they had incomplete clinical data.
Demographic and clinical data
Patient demographics, including age and sex, were col-
lected from medical records. Clinical data included initial 
laboratory data within 7 days before the start of first cycle 
of chemotherapy, including complete blood count (CBC), 
NLR, PLR, absolute neutrophil count (ANC), absolute lym-
phocyte count (ALC), absolute monocyte count (AMC), SA, 
serum lactate dehydrogenase (LDH), date of diagnosis, nodal 
involvement, bone marrow (BM) findings, presence of B 
symptoms, Eastern Cooperative Oncology Group (ECOG) 
performance status, presence of bulky disease, Ann Arbor 
stage, and IPI. Each component of CBC was counted per 
microliter, and PLR was calculated by the ratio of platelet 
count (per microliter) divided by absolute lymphocyte count 
(per microliter).
Treatment data
Treatment consisted of rituximab (375 mg/m2), cyclo-
phosphamide (750 mg/m2) and vincristine (1.4 mg/m2; max-
imum 2.0 mg), given intravenously on day 1, and oral pre-
dnisone 100 mg on days 1–5. The treatment was repeated 
every 3 weeks and continued for six or eight cycles.
Primary clinical outcome variables
The response evaluation was in accordance with the 
International Workshop for the Standardized Response 
Criteria for NHL. Overall survival (OS) was defined as date 
of diagnosis to date of death or date of last contact for those 
censored. Progression-free survival (PFS) was defined as the 
time from the date of diagnosis to the date of relapse, pro-
gression, or death from any cause.
Statistical analysis
For the numerical variables, a receiver operating character-
istic (ROC) curve was performed to estimate the optimal 
point for sensitivity/specificity towards the progression of 
MZL. Time-to-event data was estimated using the Kaplan- 
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Table 1. Demographic and clinical characteristics.
Characteristic N of patients(N=80) %
Gender
Male/female 44/36 55/45
Age (yr)
Median (range) 55 (16–81)
≥60/<60 27/53 33.7/66.3
ECOG performance status
0–1/2–3 70/10 87.5/12.5
Ann Arbor stage
III/IV 19/61 23.8/76.2
LDH
Normal/elevated 59/12 83.1/16.9
Unchecked 9
B symptom
Absent/present 72/8 90/10
BM involvement
Absent/present 56/24 70/30
IPI
1/2/3/4 23/35/16/6 28.8/43.8/
20.0/7.5
Site of involvement
Nodal MZL 12 15
MZL of MALT type
Stomach 5 6.3
Orbit 7 8.8
Lung 8 10
Small intestine 2 2.5
Large intestine 2 2.5
Parotid gland 2 2.5
Other sitea) 9 11.3
Multiple MALTs involvement 33 41.3
a)Bone, bronchus, esophagus, nasopharynx, paranasal sinus, 
peritoneum, soft tissue, thymus, thyroid (1 case of each).
Abbreviations: BM, bone marrow; ECOG, Eastern Cooperative 
Oncology Group; IPI, international prognostic index; LDH, lactate 
dehydrogenase; MALT, mucosa associated lymphoid tissue; MZL, 
marginal zone lymphoma.
Fig. 1. Kaplan-Meier graph depicting progression-free survival (PFS) of 
patients with advanced stage marginal zone lymphoma (MZL) treated 
with R-CVP chemotherapy (PFS at 3 years was 69.6%).
Meier method, and the groups were compared using the 
log-rank test. The Cox proportional hazards model was used 
to estimate the hazard ratio (HR) and the corresponding 
95% confidence interval (95% CI) in regard to the low risk 
group. Significant variables from univariate models at an 
alpha level of 5% were included in the multivariable Cox 
proportional hazards model. All reported P-values were 
two-sided, and a P-value ＜0.05 was considered significant. 
All analyses were conducted using Statistical Package for 
Social Sciences (SPSS) Version 20.0 for Windows.
RESULTS
In total, 80 patients who met the inclusion criteria were 
evaluated. Table 1 shows the clinical characteristics of the 
patients included in this analysis. The median age of the 
evaluated 80 patients (44 males and 36 females) was 55 (range, 
16–81) years. All patients were diagnosed with advanced 
clinical stage (Ann Arbor stage III or IV) lymphoma with 
19 (23.8%) at stage III and 61 (76.2%) at stage IV. Ten 
(12.5%) patients had a performance status of ≥2. Elevated 
LDH was identified in 12 (16.9%) patients. B symptoms 
(fever, night sweats, and weight loss) were observed in 8 
(10%) patients. The distributions of IPI were: 1 in 23 (28.8%); 
2 in 35 (43.8%); 3 in 16 (20%), and 4 in 6 (7.5%) patients. 
Twelve (15%) of the 80 patients had nodal MZL and 68 
(85%) had MALT lymphoma. Among patients with MALT 
lymphoma, 33 (41.3%) patients had multiple MALT site 
involvement. BM involvement was observed in 24 (30%) 
patients.
Response and survival
Fifty-nine patients (73.8%) achieved a complete remission 
(CR) and 14 (17.5%) a partial remission (PR), while stable 
disease (SD) was observed in 4 (5%) patients and progressive 
disease in 2 (2.5%) patients. One patient was not evaluable 
for response, making the ORR 91.3% (95% CI, 85.0–96.3%). 
At a median follow-up of 24.9 months (range, 0.8–75.4), 
17 patients (21.3%) had progression or relapse, and none 
died during the investigation period. Information regarding 
the treatment after disease relapse or progression was avail-
able for 15 patients. Thirteen patients received chemotherapy 
alone after relapse or progression, and two received chemo-
therapy followed with hematopoietic progenitor stem-cell 
transplantation (HPSCT). There was one patient who was 
lost to follow-up after only 1 cycle of R-CVP chemotherapy; 
therefore her data on treatment and response was not 
available. Median OS and PFS were not reached at the last 
follow-up, and PFS at 3 years was 69.6%, with the 3-year 
OS rate at 100% (Fig. 1).
Analysis of potential prognostic markers
To identify the optimal prognostic marker according to 
its sensitivity and specificity towards the relapse of MZL, 
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Table 2. Area under the curve values of prognostic marker candi-
dates.
Variables Area Std. errora)
Asymptotic 
sig.b)
Asymptotic 95% CI
Lower 
bound
Upper 
bound
Serum Albumin 0.656 0.071 0.044 0.517 0.795
AMC 0.569 0.085 0.378 0.402 0.735
ALC 0.467 0.088 0.670 0.294 0.639
ANC 0.512 0.082 0.881 0.350 0.673
PLR 0.623 0.090 0.113 0.448 0.799
Hemoglobin 0.557 0.074 0.461 0.413 0.702
NLR 0.552 0.089 0.508 0.377 0.726
a)Under the nonparametric assumption. b)Null hypothesis: true 
area=0.5.
Abbreviations: ALC, absolute lymphocyte count; AMC, absolute 
monocyte count;   ANC, absolute neutrophil count; CI, confidence 
interval; NLR, neutrophil to lymphocyte count; PLR, platelet to 
lymphocyte count.
Table 3. Univariate analysis of prognostic factors for time-to-pro-
gression.
Variables Number
PFS
HR 95% CI P a)
SA (≥3.9 vs. <3.9 g/dL) 50/30 0.243 0.086–0.691 0.008
PLR (<95 vs. ≥95) 20/60 0.298 0.114–0.779 0.014
Age (<60 vs. ≥60) 53/27 0.679 0.420–1.097 0.114
Performance status 
 (0–1 vs. 2–3)
70/10 0.629 0.297–1.331 0.225
Ann Arbor stage 
 (III vs. IV)
19/61 1.013 0.578–1.776 0.963
Elevated LDH 
 (yes vs. no)b)
12/59 1.387 0.600–3.211 0.444
B symptoms 
 (absent vs. present)
72/8 0.041 0.000–31.720 0.145
IPI (1 vs. 2–4) 23/57 0.444 0.211–0.933 0.032
Extranodal MZL 
 (yes vs. no)
68/12 0.696 0.397–1.220 0.206
a)P-value by log rank test. b)Number of patients initially evaluated 
with LDH were 71.
Abbreviations: CI, confidence interval; HR, hazard ratio; IPI, 
international prognostic index; LDH, lactate dehydrogenase; MZL, 
marginal zone lymphoma; PFS, progression free survival; PLR, 
platelet to lymphocyte ratio; SA, serum albumin.
a Receiver Operation Characteristic (ROC) curve analysis 
was performed for numerical variables (Table 2). Among 
the potential prognostic markers, only SA and PLR showed 
enough sensitivity/specificity to be put to survival rate 
analysis. For the SA, a cut-off value of 3.9 g/dL was generated 
according to the ROC analysis (sensitivity 71.0% and specific-
ity 66.6%; AUC values 0.656, 95% CI 0.517–0.795, P=0.044). 
From the ROC curve, PLR value of 95 yielded the most 
optimal value to predict the relapse or recurrence of MZL 
(sensitivity 82.3% and specificity 55.6%; AUC values 0.623, 
95% CI 0.448–0.799, P=0.113).
Univariate analysis of potential prognostic markers is 
shown in Table 3. An SA level ≥3.9 g/dL was shown to 
be a significant predictor of PFS (HR=0.243, 95% CI 0.086–
0.691, P=0.004) (Fig. 2A). PLR was also significantly prog-
nostic for PFS when evaluated for values ＜95 (HR=0.298, 
95% CI 0.114–0.779, P=0.009) (Fig. 2B). Additionally, IPI, 
when categorized by a score of 1 versus 2–4, had prognostic 
significance for PFS (HR=0.444, 95% CI 0.211–0.933, 
P=0.017) (Fig. 2C). Other candidate factors, such as age, 
performance status, Ann Arbor stage, elevation of LDH, pres-
ence of B symptoms, extranodal MZL, and BM involvement 
were not prognostic in our population.
Multivariable analysis results for PFS are shown in Table 
4. PLR continued to be an independent prognostic marker, 
with the hazard of progression for patients with PLR ＜95 
shown to be about 36.7% (95% CI 13.9–97.1) of the hazard 
for those patients with PLR ≥95, when controlling for SA 
and IPI. The SA and IPI were not prognostic for PFS in 
our multivariate analysis.
DISCUSSION
In our review of 80 patients with advanced stage MZL, 
we found that a PLR value of ≥95 may have prognostic 
significance in those treated with R-CVP. Among other can-
didates for prognostic markers of MZL, a serum albumin 
lower than 3.9 g/dL and an IPI of 2 or higher had prognostic 
value when analyzed with univariate analysis, but did not 
have enough statistical significance when applied to multi-
variate analyses.
In 1993, the International Prognostic Index (IPI) was pub-
lished [7]. Since then, IPI has been widely applied for the 
prediction of prognosis of NHLs. However, as IPI is designed 
for aggressive lymphoma and cases of indolent lymphoma 
such as MZL, as well as taking into account that the addition 
of rituximab to conventional chemotherapy has led to sig-
nificant improvements in OS and PFS in patients with MZL, 
previously studied prognostic algorithms for such patients, 
including the IPI, had to be reconstructed [9].
Other prognostic indexes, such as FLIPI used for follicular 
lymphomas, or GPS, an inflammation-based prognostic in-
dex, or MZLPI, have been proposed as alternatives for more 
indolent lymphomas [9-11]. But as our concern was focused 
on advanced stage MZL (which usually had disseminated 
disease, and hence, was a prerequisite for systemic chemo-
therapy), we did not consider prognostic indexes with Ann 
Arbor staging as a constituent.
The measurement of serum markers, such as CBC or serum 
albumin, is a simple step that could easily be employed 
in regular practice. Along with the serum markers, associa-
tion of systemic inflammatory components with tumor sur-
vival, or the pathogenesis of neoplasm itself, has been pro-
posed [20, 21]. The inflammatory parameters, namely, the 
ANC, AMC, ALC, platelet counts, NLR, PLR, CRP, serum 
albumin, and so forth are studied in many cancers for their 
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Fig. 2. Kaplan-Meier survival plots; (A) Serum albumin level ≥3.9 g/dL 
was shown to be a significant predictor of progression free survival (PFS) 
(HR=0.243, 95% CI 0.086–0.691, P=0.004); (B) PLR was also signi-
ficantly prognostic for PFS when evaluated for values of ＜95 (HR= 
0.298, 95% CI 0.114–0.779, P=0.009); (C) IPI, when categorized by a 
score of 1 versus 2–4, had prognostic significance for PFS (HR=0.444, 
95% CI 0.211–0.933, P=0.017).
Table 4. Multivariate analysis of prognostic factors for progression 
free survival. 
Variables
PFS
HR 95% CI P a)
SA (≥3.9 vs. <3.9 g/dL) 0.579 0.333–1.005 0.052
PLR (<95 vs. ≥95) 0.367 0.139–0.971 0.043
IPI (1 vs. 2–4) 0.643 0.291–1.417 0.273
a)P-value by Cox regression.
Abbreviations: CI, confidence interval; HR, hazard ratio; IPI, 
international prognostic index; PFS, progression free survival; PLR, 
platelet to lymphocyte ratio;  SA, serum albumin.
correlation with prognosis [13-16, 22, 23]. For solid tumors, 
a positive relationship between high PLR with worse prog-
nosis of epithelial ovarian cancer was identified [13, 16].
For the hematologic malignancies, similar investigations 
on the connection of inflammatory markers and the outcome 
of disease have been carried out. For patients with 
non-Hodgkin’s lymphoma, prognosis of DLBCL has been 
correlated with hypoalbuminemia, low ALC, AMC, increased 
NLR and PLR, AMC/ALC score, and GPS [15, 24-28]. 
Extranodal natural killer/T-cell lymphoma, nasal type, has 
also been shown to be related with GPS and PLR [10]. 
Outcomes of other hematologic malignancies, such as pri-
mary mediastinal large B-cell lymphoma, myelodysplastic 
syndromes, multiple myeloma, and acute myelogenous leu-
kemia have also been related to systemic inflammatory mark-
ers [29-31].
Studies regarding the correlation of inflammatory markers 
with the outcome of MZL were difficult to obtain. Four 
retrospective studies have been made regarding the prog-
nostic factors of MZL. Two studies, during their research, 
commonly deduced the result that the discriminating powers 
of formerly used prognostic scoring systems, the IPI and 
the FLIPI, are limited, if not misleading [32]. One of those 
studies by Oh et al. [9] analyzed 205 patients with nongastric 
MZL with presumed prognostic factors, PFS and OS. The 
MZLPI was constructed via the summation of speculated 
prognostic factors: nodal MZL, ECOG performance ≥2, and 
advanced stage. The PFS and OS curves were both more 
discriminating than those of IPI or FLIPI. Another study 
on the prognostic factors of nongastric MZL by Arcaini et 
al. [33] demonstrated that disease dissemination to lymph 
nodes and BM is associated with a poorer outcome. Arcaini 
et al. [34] also showed that in splenic MZL patients, low 
hemoglobin levels (＜12 g/dL), LDH levels higher than nor-
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mal, and albumin levels less than 3.5 g/dL were predictors 
of higher risk.
A study by Mazloom et al. [32] analyzed 275 patients 
with MZL by dividing them into three groups based on 
three types: extranodal, nodal, and splenic. The results 
showed that an elevated serum β2-microglobulin level, B 
symptoms, and male gender were found to be correlated 
with decreased recurrence-free survival (RFS). Using these 
three variables, they formulated a 3-tier prognostic scoring 
system for extranodal MZL, which had statistically reason-
able discriminating power (P=0.01 for RFS, P＜0.0001 for 
OS). Their study also showed that IPI and FLIPI did not 
have statistical significance regarding OS of MZL.
None of the above-mentioned studies regarding the prog-
nosis of MZL considered the previously emphasized role 
of inflammatory markers on malignancy development and 
progression. Groundwork investigations on the roles of plate-
lets in tumor spreading and growth have shown that platelets 
mediate tumor cell growth, dissemination, and angiogenesis 
[18]. Investigators have suggested that platelets play a role 
in the homing of circulating tumor cells to distant organs 
and that platelet interactions with tumor cells lead to rolling 
and tethering of tumor cell aggregates, resulting in ex-
travasation through the endothelial wall and immune pro-
tection [35]. Platelets have also been shown to promote the 
spread of tumors through multiple mechanisms, including 
selectin and integrin interactions with tumor cells [36]. In 
addition to their function in hemostasis, platelets are also 
involved in inflammatory disease and cancer [37].
In contrast to platelets, lymphocytes are considered a sig-
nificant blood parameter related to immune surveillance. 
High lymphocytic infiltrate is associated with improved sur-
vival and superior response to systemic therapy [38], whereas 
low peripheral blood lymphocyte counts are related to poor 
cancer prognoses [39].
Our findings provide a new approach in predicting out-
comes in MZL patients. Prediction of disease progression 
not only utilizing clinical or histopathological factors (e.g., 
tumor grade, tumor size, and tumor site), but also with 
host-response factors, such as systemic inflammatory mark-
ers, may have more clinical significance. Furthermore, the 
PLR can easily be assessed from peripheral blood tests that 
are available without additional expenditure, thus providing 
lower cost and greater convenience for predicting prognosis.
However, this study has some limitations, including the 
few deaths caused by MZL, the relatively small size of the 
analysis group, and the inherent bias that exists in a retro-
spective study. To verify the results of this study, a collective 
effort by way of a multi-institutional prospective study with 
longer follow-up will be needed. However, given the lack 
of prospective data, this retrospective study provides evi-
dence to support the role of these prognostic factors and 
provides novel insight into predicting outcomes in MZL 
patients.
In conclusion, our study is the first to show that PLR 
is an independent prognostic marker in patients with MZL 
treated with R-CVP chemo-immunotherapy.
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